ESPAC-4: Adjuvant Gemcitabine/Capecitabine in Resected Pancreatic Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.

Results of the phase III ESPAC-4 trial found that resected pancreatic cancer patients treated with the gemcitabine plus capecitabine had a better estimated 5-year survival rate compared with those treated with gemcitabine alone.

The data (abstract LBA4006) were presented by John P. Neoptolemos, MA, MB, BChir, MD, of the University of Liverpool in the United Kingdom, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago. In this video Dr. Neoptolemos discusses the results of the trial as well as the next steps in pancreatic cancer research.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

RP1/Nivolumab Combo Shows Responses in Advanced Pretreated Melanoma

Ashley Chan
June 8th 2025
Article

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Roman Fabbricatore
June 5th 2025
Article

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

Kristi Rosa
June 3rd 2025
Article

Compared with nivolumab alone, nivolumab/relatlimab did not improve RFS in patients with resected stage III to IV melanoma.

SCRT/Chemo Produce Positive Responses in Locally Advanced Rectal Cancer

SCRT/Chemo Produce Positive Responses in Locally Advanced Rectal Cancer

Ariana Pelosci
June 3rd 2025
Article

Results from the ShorTrip trial found that SCRT plus chemotherapy regimens showed promising efficacy for patients with locally advanced rectal cancer.